Combined nasal administration of encephalitogenic myelin basic protein peptide 68-86 and IL-10 suppressed incipient experimental allergic encephalomyelitis in Lewis rats

Clin Immunol. 2000 Sep;96(3):205-11. doi: 10.1006/clim.2000.4895.


Mucosal administration of low doses of myelin basic protein (MBP) peptide 68-86 (MBP 68-86) or anti-inflammatory cytokine IL-10 effectively prevented experimental allergic encephalomyelitis (EAE), but failed to suppress the disease if given after 7 days postimmunization (p.i.), i.e., after T cell priming had occurred. We anticipated that combined administration of autoantigen and IL-10 can treat incipient EAE. Lewis rats with EAE actively induced with MBP 68-86 and complete Freund's adjuvant received 120 microg MBP 68-86 + 200 ng IL-10 per rat per day from day 7 p.i. and for 5 consecutive days. These rats showed later onset, lower clinical scores, less body weight loss, and shorter duration of EAE than rats receiving MBP 68-86 or IL-10 only or PBS. EAE amelioration was associated with decreased infiltration of ED1(+) macrophages and CD4(+) T cells within the central nervous system and with decreased proliferative responses of lymph node cells, indicating that combined administration of MBP 68-86 and IL-10 induced immune hyporesponsiveness. IFN-gamma secretion as well as IFN-gamma, TNF-alpha, IL-4, and IL-10 mRNA expression by lymph node MNC was down-regulated in the treated rats. Immune hyporesponsiveness, rather than immune deviation or regulatory mechanisms, seems to be responsible for the protection of EAE after autoantigen + IL-10 administration by the nasal route.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Intranasal
  • Administration, Oral
  • Animals
  • Antigens / pharmacology
  • Cytokines / genetics
  • Drug Therapy, Combination
  • Encephalomyelitis, Autoimmune, Experimental / drug therapy*
  • Encephalomyelitis, Autoimmune, Experimental / immunology
  • Encephalomyelitis, Autoimmune, Experimental / prevention & control
  • Immune Tolerance / drug effects
  • Immunohistochemistry
  • Interferon-gamma / metabolism
  • Interleukin-10 / administration & dosage*
  • Interleukin-10 / therapeutic use*
  • Lymph Nodes / cytology
  • Lymphocyte Activation / drug effects
  • Monocytes / chemistry
  • Myelin Basic Protein / administration & dosage*
  • Myelin Basic Protein / therapeutic use*
  • Peptide Fragments / administration & dosage*
  • Peptide Fragments / therapeutic use*
  • RNA, Messenger / metabolism
  • Rats
  • Rats, Inbred Lew
  • Th1 Cells / metabolism


  • Antigens
  • Cytokines
  • Myelin Basic Protein
  • Peptide Fragments
  • RNA, Messenger
  • myelin basic protein 68-86
  • Interleukin-10
  • Interferon-gamma